CEO of Urologix Inc. (ULGX, Financial) Stryker Jr Warren buys 16,900 shares of ULGX on 12/07/2009 at an average price of $1.13 a share.
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than twenty three million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron control units and the Cooled ThermoCath, Targis and Prostaprobe catheter families. Additionally, Urologix is currently developing CoolMax, its next generation microwave catheter for in-office benign prostatic hyperplasia treatment. All of Urologix' products utilize Cooled ThermoTherapy targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort and provide safe, effective, lasting relief of the symptoms of benign prostatic hyperplasia. Urologix Inc. has a market cap of $18 million; its shares were traded at around $1.24 with and P/S ratio of 1.4.
ULGX is in the portfolios of Chuck Royce of ROYCE & ASSOCIATES.
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than twenty three million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron control units and the Cooled ThermoCath, Targis and Prostaprobe catheter families. Additionally, Urologix is currently developing CoolMax, its next generation microwave catheter for in-office benign prostatic hyperplasia treatment. All of Urologix' products utilize Cooled ThermoTherapy targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort and provide safe, effective, lasting relief of the symptoms of benign prostatic hyperplasia. Urologix Inc. has a market cap of $18 million; its shares were traded at around $1.24 with and P/S ratio of 1.4.
ULGX is in the portfolios of Chuck Royce of ROYCE & ASSOCIATES.
Insiders' Positions with ULGX
- Buy:: CEO Stryker Jr Warren bought 3,100 shares of ULGX stock on 12/03/2009 at the average price of 1.12, the price of the stock has increased by 10.71% since
- Buy:: CEO Stryker Jr Warren bought 1,870 shares of ULGX stock on 09/01/2009 at the average price of 1.2, the price of the stock has increased by 3.33% since
- Buy:: CEO Stryker Jr Warren bought 1,635 shares of ULGX stock on 08/28/2009 at the average price of 1.2, the price of the stock has increased by 3.33% since
Insiders' Positions with ULGX
- Buy:: Director William M Moore bought 20,000 shares of ULGX stock on 11/17/2009 at the average price of 0.98, the price of the stock has increased by 26.53% since
